
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is supported by a broad, diversified portfolio that is delivering both scale and innovation, as 3Q 2026 sales of $10.37B and EPS of $6.45 beat expectations while the company raised FY 2026 guidance to $38.9B-$39.7B in sales and $22.90-$23.70 in non-GAAP EPS. Growth is being led by newer assets such as Imdelltra, which generated $406M and showed compelling clinical data in 1L ES-SCLC, alongside Uplizna, while the expanding biosimilar franchise added another layer of recurring momentum. The firm also appears financially resilient, with operating margin guidance of ~45%-46% and management signaling no step-down in 2027, supporting confidence in durable earnings power despite some offsets from Tepezza, Prolia, and Xgeva.
Bears say
Amgen is facing multiple fundamental headwinds that justify a negative outlook, with the text explicitly flagging downside risks from disappointing MariTide data, stronger competitor obesity drugs, faster biosimilar erosion of Prolia and Xgeva, adverse IRS litigation outcomes, and tariff developments. Confidence in its long-duration growth pipeline is also pressured by read-through risk from pelacarsen’s primary-endpoint miss, since weak Lp(a) outcome data would further undermine optimism around olpasiran’s 2028 trial. Meanwhile, the company’s legacy franchises already show erosion in key markets, and the cited revenue trajectories point to meaningful year-over-year declines in several segments, suggesting that newer launches may not offset loss of exclusivity and competitive pressure quickly enough.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Amgen (AMGN) Forecast
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares